This inventor holds 1 USPTO granted patent. Top assignee: Societe Des Produits Nestle S.a.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Max Scherer: Innovator in Biomarker Research
Introduction
Max Scherer is a notable inventor based in Ottobrunn, Germany. He has made significant contributions to the field of biomarker research, particularly in relation to epicardial adipose tissue. His innovative work has the potential to impact medical diagnostics and treatment strategies.
Latest Patents
Max Scherer holds a patent for a method that predicts the level of epicardial adipose tissue (EAT) in a subject. The patent, titled "Biomarkers for epicardial adipose tissue," outlines a process that involves determining the levels of specific lipid biomarkers in a sample from the subject. The biomarkers include phosphatidylcholine (PC) [16:1/16:1], diacylglycerol (DAG) [42:8], phosphatidylethanolamine-ether (PE-O) [32:5], phosphatidylcholine (PC) [18:0/22:5], phosphatidylinositol (PI) [18:0/16:1], phosphatidylglycerol (PG) [20:3/20:3], and phosphatidylglycerol (PG) [22:5/18:1]. By comparing the levels of these biomarkers to reference values, the method provides insights into the levels of EAT fat in the subject.
Career Highlights
Max Scherer is currently employed at Société des Produits Nestlé S.A., where he continues to advance his research in biomarker development. His work is instrumental in enhancing the understanding of adipose tissue and its implications for health.
Collaborations
Max collaborates with talented colleagues, including Fiona Camille Beguelin and Ivan Montoliu Roura. Their combined expertise fosters a productive research environment that drives innovation in their field.
Conclusion
Max Scherer is a pioneering inventor whose work on biomarkers for epicardial adipose tissue holds promise for improving health diagnostics. His contributions to the field are noteworthy and reflect his commitment to advancing medical science.